JP2018508084A - 逆指向分析(Reversed−directedanalysis)による証拠に基づく植物の有効成分の検出方法 - Google Patents
逆指向分析(Reversed−directedanalysis)による証拠に基づく植物の有効成分の検出方法 Download PDFInfo
- Publication number
- JP2018508084A JP2018508084A JP2017548209A JP2017548209A JP2018508084A JP 2018508084 A JP2018508084 A JP 2018508084A JP 2017548209 A JP2017548209 A JP 2017548209A JP 2017548209 A JP2017548209 A JP 2017548209A JP 2018508084 A JP2018508084 A JP 2018508084A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- compounds
- patients
- herbs
- analyzing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4854—Diagnosis based on concepts of traditional oriental medicine
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/90—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Alternative & Traditional Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Evolutionary Biology (AREA)
- Artificial Intelligence (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
伝統的な漢方薬(TCM)は、中国人の健康に不可欠な貢献をした。TCMは自然薬である。その効果は、単一または複数の化学成分によって達成される固有の物質的基盤を持たなければならない。薬草(ハーブともいう)は非常に複雑な化学組成を持っている。1つの薬草は何百種もの未知化合物で構成されており、TCMは数種または数十種の薬草で構成されている。TCMを研究する古典的な方法は、薬草から単一の化学成分を抽出し、次いで成分の活性をインビボまたはインビトロで1つずつ分析することである。しかし、この方法は、代謝産物の安全性および有効性を検出することができず、TCMの異なる化合物間の相乗効果も検出できない。高圧液体クロマトグラフィー(HPLC)、ガスクロマトグラフィー-質量分析、液体クロマトグラフィー-質量分析、液体クロマトグラフィー-質量-質量分析(LCMS-MS)、指紋など、ハーブの化合物を分析する方法は数多くある。しかしながら、これらの方法は、それらの化学組成物に対応するピークのみを同定することができ、それらを有効性および安全性と関連付けることはできない。したがって、このような材料ベースは、TCM研究において依然としてボトルネックである。
本発明のより完全な理解のために、以下の記載に言及する。
最高濃度は別の時に血液のサンプルを計ることで得られ、C1-C4の適当な投与量が決められる。
1.これら患者は、第一の調合で好適な反応をもたない仮説的な対象である。
2.これらのバイオマーカーは、仮説的なものである。
3.BP:血圧。
4. W、Y、Z成分は、正常範囲内でこれら患者に存在するので、これらの成分を投与する理由はない。
Claims (10)
- 伝統的な漢方薬に存在する活性成分を同定する方法であって、
患者の状態、診断及び処置を含む患者データの記録の実施をウェブサイトを通じてプロバイダーに可能にするためにウェブサイトをセットアップする工程を含み、ここで該プロバイダーは該患者のデータをダウンロードすることができ;
有効な薬草の組み合わせ見出し、そして意味のない薬草を排除するために、ANOVA、ANCOVA、ロジスティック回帰、時系列、R-スクエアから選ばれる手段によって、該データの統計分析を実行し;
当該組成物内の化合物を合成若しくは分離することで、これら薬草の組成を分析し;
活性成分を決定するために、内部及び外部の両方のテストを行い、そして、純粋な有効化合物で若しくはその薬草との組み合わせで、規制当局の認可若しくは認可なしに、その医学的状態について、患者を処置し;
患者において有効化合物が同定される - 該ウェブサイトは、全ての医学的実務家に、実務情報を入力すること及び該ウェブサイトからダウンロードされた該データをもとに統計分析行うことを許容するようにセットアップされ、そして、該実務家は、繰り返し、診断及び処置の継続的改良をおこなうことが可能であり、そしてどの薬草が患者に有効な効果をもち安全か及びどの薬草が患者に安全だが効果がないかを決定することが可能である、請求項1に記載の方法。
- さらに、化学的分析装置で患者の血液検体を分析し、そして、コンピュータプログラムを経て、肯定的な結果をもつ、これら患者の共通の組成物をみいだすことを含む、請求項1に記載の方法。
- さらに、ANOVA、ANCOVA、ロジスティック回帰、時系列、R-スクエアから選ばれる一つを含む、統計解析法により該化合物の重要でない組成を分析し、排除することを含む、請求項1に記載の方法。
- さらに、これら有効でない患者の血液検体を分析し、これら共通の組成をもつ者を見出すことを含む、請求項1の方法。
- さらに、これら共通の化合物が、肯定的および否定的結果を有する患者に存在する様々な化合物間の差異によって、内部及び外部の両方のテストで効果があるどうかを決定することを含む、請求項1に記載の方法。
- さらに、患者の生物学的特性に応じて精製された化合物を用いて内部および外部テストを行うことを含む、請求項1に記載の方法。
- さらに、その異なる生物学的特性に従って見出された活性化合物で患者を処置することを含む、請求項1に記載の方法。
- さらに、該精製された活性化合物のみを使用することによって、またはオリジナルの薬草と精製した物質との組み合わせで患者を処置することを含む、請求項1の方法。
- ここで、有効な化合物は、規制当局によって承認された後、又は承認なしで特許物質として、又はトレードシークレットとして、関連医学的状態について患者を処置するために使用されうる、請求項1に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562177349P | 2015-03-13 | 2015-03-13 | |
US62/177,349 | 2015-03-13 | ||
US14/866,924 | 2015-09-26 | ||
US14/866,924 US20160085941A1 (en) | 2015-03-13 | 2015-09-26 | Method of Discovery of Effective Components in Herbals Based on Evidences by Reversed-directed Analysis |
PCT/US2016/020789 WO2016148936A1 (en) | 2015-03-13 | 2016-03-03 | Method of discovery of effective components in herbals based on evidences by reversed-directed analysis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018508084A true JP2018508084A (ja) | 2018-03-22 |
JP2018508084A5 JP2018508084A5 (ja) | 2019-05-09 |
Family
ID=55525998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017548209A Pending JP2018508084A (ja) | 2015-03-13 | 2016-03-03 | 逆指向分析(Reversed−directedanalysis)による証拠に基づく植物の有効成分の検出方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20160085941A1 (ja) |
EP (1) | EP3268926A4 (ja) |
JP (1) | JP2018508084A (ja) |
CN (1) | CN108351328A (ja) |
AU (1) | AU2016233772A1 (ja) |
WO (1) | WO2016148936A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021132988A1 (ko) * | 2019-12-27 | 2021-07-01 | 한국식품연구원 | 식치 정보의 관리 방법 및 장치 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001357131A (ja) * | 2000-06-12 | 2001-12-26 | Kanai Tokichi Shoten:Kk | 通信ネットワークを介して漢方薬の処方を提供する方法 |
JP2008097154A (ja) * | 2006-10-06 | 2008-04-24 | Fujitsu Ltd | 相互作用分析プログラムおよび相互作用分析装置 |
JP2010524055A (ja) * | 2007-03-30 | 2010-07-15 | 9898リミテッド | 天然物開発のための薬剤プラットフォーム技術 |
JP2013012025A (ja) * | 2011-06-29 | 2013-01-17 | Fujifilm Corp | 診療支援システムおよび方法、並びに、プログラム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6113907A (en) * | 1997-04-15 | 2000-09-05 | University Of Southern California | Pharmaceutical grade St. John's Wort |
EP1006802A4 (en) * | 1997-08-28 | 2004-01-14 | Cv Technologies Inc | CHEMICAL AND PHARMACOLOGICAL STANDARDIZATION OF PLANT EXTRACTS |
JPH11193240A (ja) * | 1997-12-26 | 1999-07-21 | Meiji Milk Prod Co Ltd | 脂質代謝改善組成物 |
US20050283385A1 (en) * | 2004-06-21 | 2005-12-22 | The Permanente Medical Group, Inc. | Individualized healthcare management system |
US20150339442A1 (en) * | 2013-12-04 | 2015-11-26 | Mark Oleynik | Computational medical treatment plan method and system with mass medical analysis |
-
2015
- 2015-09-26 US US14/866,924 patent/US20160085941A1/en not_active Abandoned
-
2016
- 2016-03-03 JP JP2017548209A patent/JP2018508084A/ja active Pending
- 2016-03-03 CN CN201680003852.3A patent/CN108351328A/zh active Pending
- 2016-03-03 WO PCT/US2016/020789 patent/WO2016148936A1/en active Application Filing
- 2016-03-03 AU AU2016233772A patent/AU2016233772A1/en not_active Abandoned
- 2016-03-03 EP EP16765419.3A patent/EP3268926A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001357131A (ja) * | 2000-06-12 | 2001-12-26 | Kanai Tokichi Shoten:Kk | 通信ネットワークを介して漢方薬の処方を提供する方法 |
JP2008097154A (ja) * | 2006-10-06 | 2008-04-24 | Fujitsu Ltd | 相互作用分析プログラムおよび相互作用分析装置 |
JP2010524055A (ja) * | 2007-03-30 | 2010-07-15 | 9898リミテッド | 天然物開発のための薬剤プラットフォーム技術 |
JP2013012025A (ja) * | 2011-06-29 | 2013-01-17 | Fujifilm Corp | 診療支援システムおよび方法、並びに、プログラム |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021132988A1 (ko) * | 2019-12-27 | 2021-07-01 | 한국식품연구원 | 식치 정보의 관리 방법 및 장치 |
KR20210083945A (ko) * | 2019-12-27 | 2021-07-07 | 한국식품연구원 | 식치 정보의 관리 방법 및 장치 |
KR102376173B1 (ko) * | 2019-12-27 | 2022-03-21 | 한국식품연구원 | 식치 정보의 관리 방법 및 장치 |
Also Published As
Publication number | Publication date |
---|---|
AU2016233772A1 (en) | 2017-08-17 |
EP3268926A1 (en) | 2018-01-17 |
WO2016148936A1 (en) | 2016-09-22 |
WO2016148936A8 (en) | 2017-03-30 |
US20160085941A1 (en) | 2016-03-24 |
EP3268926A4 (en) | 2018-12-05 |
CN108351328A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bossong et al. | Association of hippocampal glutamate levels with adverse outcomes in individuals at clinical high risk for psychosis | |
Liu et al. | Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis | |
Meissner et al. | Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis | |
Chen et al. | Effects of mindfulness-based stress reduction on sleep quality and mental health for insomnia patients: a meta-analysis | |
Landgrebe et al. | The Tinnitus Research Initiative (TRI) database: a new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome | |
Bouchard et al. | Blood lead levels and major depressive disorder, panic disorder, and generalized anxiety disorder in US young adults | |
Zeng et al. | Ginkgo biloba for acute ischaemic stroke | |
Phillips et al. | Prediction of breast cancer risk with volatile biomarkers in breath | |
Jepson et al. | Garlic for peripheral arterial occlusive disease | |
Koch et al. | Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate Alzheimer disease: a randomized clinical trial | |
Boutté et al. | Neurotrauma biomarker levels and adverse symptoms among military and law enforcement personnel exposed to occupational overpressure without diagnosed traumatic brain injury | |
Sung et al. | Parkinson disease: a systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation | |
Lengelé et al. | Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year period in the SarcoPhAge cohort | |
Kleefstra et al. | Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients (ZODIAC-17) | |
Waffenschmidt et al. | Simple search techniques in PubMed are potentially suitable for evaluating the completeness of systematic reviews | |
Hormozi et al. | Investigating relationship between pre-and post-chemotherapy cognitive performance with levels of depression and anxiety in breast cancer patients: A cross-sectional study | |
Tsuruta et al. | Cross‐sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor‐α inhibitors | |
Franceschetti et al. | Drugs in bone: Detectability of substances of toxicological interest in different states of preservation | |
Kristensen et al. | Sensory and motor axonal excitability testing in early diabetic neuropathy | |
Kural et al. | The utility of a point‐of‐care sural nerve conduction device for detection of diabetic polyneuropathy: A cross‐sectional study | |
Alsubaie et al. | Prevalence of obsessive compulsive disorder: a survey with Southern Saudi Arabian samples | |
JP2018508084A (ja) | 逆指向分析(Reversed−directedanalysis)による証拠に基づく植物の有効成分の検出方法 | |
Narendran et al. | Imaging cortical dopamine transmission in cocaine dependence: a [11C] FLB 457–amphetamine positron emission tomography study | |
Rodríguez-Fuentes et al. | Oral microbiome and systemic antineoplastics in cancer treatment: A systematic review | |
Hunter et al. | Neurophysiologic effects of repeated exposure to antidepressant medication: are brain functional changes during antidepressant administration influenced by learning processes? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190301 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200518 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201019 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210215 |